Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115788 | 1.00 | ACE (0.50) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5115696 | 0.91 | ACE (0.50) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5774374 | 0.91 | ACE (0.50) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL16909032 | 0.86 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL14343235 | 0.86 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1087185 | 0.86 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5111794 | 0.85 | ITGB3 (0.52) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5111802 | 0.85 | ITGB3 (0.52) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL19493067 | 0.84 | ACE (0.53) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL7105276 | 0.84 | ACE (0.68) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | ACE 220/4885ITGB3 2541/4885ITGA2B 4638/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | ACE 220/4885ITGB3 2541/4885ITGA2B 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.